The European Medicines Agency (EMEA) is to develop detailed guidance on the manufacture, market approval and use of drugs that can treat alcoholism, given that no such formal advice currently exists at a European Union (EU)-level.

The guidance will focus on clearly defining target patients, treatment success (whether drugs should end alcoholism, or also reduce drinking), and drug research project organisation.

The EMEA will also advise whether certain age groups should be excluded from such treatment, as well as patients suffering from other illnesses.

Existing treatments include Acamprosate, currently prescribed in the EU for preventing a recurrence of alcoholism, while other medicines are currently in development.